Irinotecan versus oxaliplatin for adjuvant colon cancer therapy: Why do the results differ?

Sujatha Nallapareddy, S. Gail Eckhardt, Wells Messersmith

Research output: Contribution to journalReview article

Abstract

Chemotherapy for colon cancer has evolved substantially over the past 5 years with the addition of new drugs such as oxaliplatin and irinotecan. Though chemotherapy regimens based on oxaliplatin and irinotecan are considered to be equivalent in the advanced- disease setting, oxaliplatin-based regimens appear more effective in adjuvant therapy after resection. The MOSAIC and NSABP C-07 trials demonstrated survival improvement with the addition of oxaliplatin, whereas the CALGB 89803, ACCORD-02, and PETACC-3 trials did not reveal the same benefi t with irinotecan. This discrepancy may stem from differences in the mechanism of action, drug resistance, toxicity, or trial design. These results challenge the conventional wisdom that agents effective in the advanced setting will work postopera-tively. With the availability of new, targeted agents, it is clear that the results of randomized phase 3 trials must be analyzed before extrapolating effi cacy from the meta-static setting to the adjuvant setting in colon cancer.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalCurrent Colorectal Cancer Reports
Volume4
Issue number3
DOIs
StatePublished - Jul 1 2008

Fingerprint

irinotecan
oxaliplatin
Colonic Neoplasms
Drug Therapy
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Drug Resistance

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Cite this

Irinotecan versus oxaliplatin for adjuvant colon cancer therapy : Why do the results differ? / Nallapareddy, Sujatha; Eckhardt, S. Gail; Messersmith, Wells.

In: Current Colorectal Cancer Reports, Vol. 4, No. 3, 01.07.2008, p. 167-172.

Research output: Contribution to journalReview article

@article{ef10e8f06b4f497cbb4ef55c64897e9f,
title = "Irinotecan versus oxaliplatin for adjuvant colon cancer therapy: Why do the results differ?",
abstract = "Chemotherapy for colon cancer has evolved substantially over the past 5 years with the addition of new drugs such as oxaliplatin and irinotecan. Though chemotherapy regimens based on oxaliplatin and irinotecan are considered to be equivalent in the advanced- disease setting, oxaliplatin-based regimens appear more effective in adjuvant therapy after resection. The MOSAIC and NSABP C-07 trials demonstrated survival improvement with the addition of oxaliplatin, whereas the CALGB 89803, ACCORD-02, and PETACC-3 trials did not reveal the same benefi t with irinotecan. This discrepancy may stem from differences in the mechanism of action, drug resistance, toxicity, or trial design. These results challenge the conventional wisdom that agents effective in the advanced setting will work postopera-tively. With the availability of new, targeted agents, it is clear that the results of randomized phase 3 trials must be analyzed before extrapolating effi cacy from the meta-static setting to the adjuvant setting in colon cancer.",
author = "Sujatha Nallapareddy and Eckhardt, {S. Gail} and Wells Messersmith",
year = "2008",
month = "7",
day = "1",
doi = "10.1007/s11888-008-0027-9",
language = "English (US)",
volume = "4",
pages = "167--172",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Irinotecan versus oxaliplatin for adjuvant colon cancer therapy

T2 - Why do the results differ?

AU - Nallapareddy, Sujatha

AU - Eckhardt, S. Gail

AU - Messersmith, Wells

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Chemotherapy for colon cancer has evolved substantially over the past 5 years with the addition of new drugs such as oxaliplatin and irinotecan. Though chemotherapy regimens based on oxaliplatin and irinotecan are considered to be equivalent in the advanced- disease setting, oxaliplatin-based regimens appear more effective in adjuvant therapy after resection. The MOSAIC and NSABP C-07 trials demonstrated survival improvement with the addition of oxaliplatin, whereas the CALGB 89803, ACCORD-02, and PETACC-3 trials did not reveal the same benefi t with irinotecan. This discrepancy may stem from differences in the mechanism of action, drug resistance, toxicity, or trial design. These results challenge the conventional wisdom that agents effective in the advanced setting will work postopera-tively. With the availability of new, targeted agents, it is clear that the results of randomized phase 3 trials must be analyzed before extrapolating effi cacy from the meta-static setting to the adjuvant setting in colon cancer.

AB - Chemotherapy for colon cancer has evolved substantially over the past 5 years with the addition of new drugs such as oxaliplatin and irinotecan. Though chemotherapy regimens based on oxaliplatin and irinotecan are considered to be equivalent in the advanced- disease setting, oxaliplatin-based regimens appear more effective in adjuvant therapy after resection. The MOSAIC and NSABP C-07 trials demonstrated survival improvement with the addition of oxaliplatin, whereas the CALGB 89803, ACCORD-02, and PETACC-3 trials did not reveal the same benefi t with irinotecan. This discrepancy may stem from differences in the mechanism of action, drug resistance, toxicity, or trial design. These results challenge the conventional wisdom that agents effective in the advanced setting will work postopera-tively. With the availability of new, targeted agents, it is clear that the results of randomized phase 3 trials must be analyzed before extrapolating effi cacy from the meta-static setting to the adjuvant setting in colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=84873397911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873397911&partnerID=8YFLogxK

U2 - 10.1007/s11888-008-0027-9

DO - 10.1007/s11888-008-0027-9

M3 - Review article

AN - SCOPUS:84873397911

VL - 4

SP - 167

EP - 172

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -